胃轻瘫药物市场规模、份额和成长分析（按类型、药物类别、给药途径、应用、分销管道和地区划分）—产业预测（2026-2033 年）

全球胃轻瘫药物市场规模预计在 2024 年达到 60.1 亿美元，从 2025 年的 63.4 亿美元增长到 2033 年的 97.4 亿美元，在预测期（2026-2033 年）内复合年增长率为 5.5%。

全球胃轻瘫药物市场持续稳定成长，主要受糖尿病盛行率上升（糖尿病是胃轻瘫的主要诱因）以及人们对消化器官系统疾病日益增长的认识所驱动。此外，非侵入性、针对性治疗方法的趋势也促进了这一增长。质子帮浦阻断剂和促动力药物因其能有效缓解噁心和排放延迟等症状，成为关键药物类别。糖尿病性胃轻瘫市场尤其突出，反映了糖尿病相关併发症的整体趋势。儘管零售药局仍然是主要的通路，但线上药局因其便利性而日益受到关注。北美市场占据主导地位，这得益于其完善的医疗保健体系、高诊断率和积极的监测机制；欧洲也贡献显着，尤其是在诊断技术和患者照护的进步。

全球胃轻瘫药物市场驱动因素

推动全球胃轻瘫药物市场成长的关键因素之一是糖尿病盛行率的不断上升，而糖尿病与胃轻瘫密切相关。随着全球1型和第2型糖尿病患者数量的增加，糖尿病性胃轻瘫等併发症的发生率也在上升，增加了对治疗的需求。这一趋势促使製药公司加强生产针对糖尿病性胃轻瘫的标靶治疗，凸显了市场对有效解决方案的迫切需求，因为医疗保健机构正在努力应对这一疾病日益沉重的负担。

全球胃轻瘫药物市场面临的限制因素

全球胃轻瘫药物市场面临许多挑战，因为许多现有药物主要针对缓解症状，且可能产生不良副作用，导致长期使用受限，患者满意度降低。监管环境也构成另一道障碍，许多新型候选疗法因难以证明其足够的长期安全性而受挫。这凸显了开发创新且安全的胃轻瘫疗法的复杂性，并强调了推进能够有效兼顾疗效和耐受性的治疗方案至关重要。

全球胃轻瘫药物市场趋势

人工智慧（AI）在药物研发和临床试验的应用是全球胃轻瘫药物市场的一大趋势。 AI技术透过更精准地识别分子标靶和优化试验设计以适应胃轻瘫的复杂性，正在改善药物研发环境。这种方法不仅有助于简化药物研发流程，还能降低成本并提高病患招募效率。随着製药公司积极采用AI驱动的调查方法，市场有望加速创新，并涌现出更多更有效的治疗方案，最终加快新治疗方法的研发，为饱受这种棘手疾病折磨的患者提供更完善的解决方案。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球胃轻瘫药物市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 品牌产品
• 学名药

全球胃轻瘫药物市场规模（按药物类别和复合年增长率划分）（2026-2033 年）

• 氨基水杨酸盐
• 消化酵素
• 质子帮浦阻断剂
• 泻药
• 止吐药
• H2受体拮抗剂
• 止泻药
• 生物製药/生物相似药
• 其他的

全球胃轻瘫药物市场规模（按给药途径和复合年增长率划分）（2026-2033 年）

• 口服
• 注射
• 其他的

全球胃轻瘫药物市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 克隆氏症
• 溃疡性大肠炎
• GERD
• IBS
• 其他的

全球胃轻瘫药物市场规模（按分销管道和复合年增长率划分）（2026-2033 年）

• 医院药房
• 零售药房
• 网路药房

全球胃轻瘫药物市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• AbbVie Inc.（USA）
• Evoke Pharma, Inc.（USA）
• Vanda Pharmaceuticals Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• AstraZeneca PLC（UK）
• GlaxoSmithKline PLC（GSK）（UK）
• Neurogastrx Inc.（USA）
• Processa Pharmaceuticals, Inc.（USA）
• Abbott Laboratories（USA）
• Bausch Health Companies Inc.（Canada）
• Rhythm Pharmaceuticals, Inc.（USA）
• CinDome Pharma（USA）
• ANI Pharmaceuticals, Inc.（USA）
• Johnson & Johnson Inc.（USA）
• Pfizer Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Medtronic PLC（Ireland）
• Otsuka Pharmaceutical Co. Ltd.（Japan）
• Theravance Biopharma, Inc.（USA）
• Cadila Pharmaceuticals（India）

结论与建议

Global Gastroparesis Drugs Market size was valued at USD 6.01 Billion in 2024 and is poised to grow from USD 6.34 Billion in 2025 to USD 9.74 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The global gastroparesis drugs market is witnessing consistent growth, largely fueled by the rising prevalence of diabetes, a major contributor to the condition, alongside increased awareness surrounding gastrointestinal issues. This growth is also supported by a shift towards non-invasive and symptom-specific therapies. Proton pump inhibitors and prokinetic agents are leading drug classes due to their efficacy in alleviating symptoms such as nausea and delayed gastric emptying. The diabetic gastroparesis segment is particularly prominent, reflecting the broader trend of diabetes-related complications. While retail pharmacies remain the primary distribution avenue, online pharmacies are gaining traction for their convenience. North America dominates the market, aided by robust healthcare systems, high diagnosis rates, and proactive research, with Europe also contributing significantly, particularly in diagnostics and patient care advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastroparesis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastroparesis Drugs Market Segments Analysis

Global Gastroparesis Drugs Market is segmented by Type, Drug Class, Route of Administration, Application, Distribution Channel and region. Based on Type, the market is segmented into Branded and Generics. Based on Drug Class, the market is segmented into Amino salicylates, Digestive enzymes, Proton Pump Inhibitors, Laxatives, Anti-Emetics, H2 Antagonists, Anti-Diarrheal, Biologics/Biosimilar and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on Application, the market is segmented into Crohn's disease, Ulcerative colitis, GERD, IBS and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastroparesis Drugs Market

A significant factor propelling the global gastroparesis drugs market is the increasing prevalence of diabetes, which is intricately associated with gastroparesis. With a growing number of individuals diagnosed with both Type 1 and Type 2 diabetes around the world, the occurrence of complications such as diabetic gastroparesis is also rising, creating a greater demand for medical treatments. This trend encourages pharmaceutical companies to enhance their production of targeted therapies aimed at managing diabetic gastroparesis, highlighting the urgent need for effective solutions in the market as healthcare providers respond to the rising burden of this condition.

Restraints in the Global Gastroparesis Drugs Market

The Global Gastroparesis Drugs market faces significant challenges due to the fact that many existing medications primarily provide symptomatic relief and can lead to undesirable side effects, which in turn restricts their long-term usage and diminishes patient satisfaction. The regulatory landscape poses additional obstacles, as evidenced by the setbacks experienced by new treatment candidates that struggle to demonstrate adequate long-term safety. This underscores the complexities involved in developing innovative, safe therapies for gastroparesis and highlights the critical need for advancements in treatment options that can effectively address both efficacy and tolerability for patients.

Market Trends of the Global Gastroparesis Drugs Market

The Global Gastroparesis Drugs market is witnessing a significant trend towards the integration of artificial intelligence in drug discovery and clinical trials. AI technologies are enhancing the pharmaceutical R&D landscape by enabling more precise identification of molecular targets and optimizing trial designs tailored to the complexities of gastroparesis. This approach not only streamlines the drug development process but also reduces costs and improves patient enrollment efficiency. As pharmaceutical companies increasingly adopt AI-driven methodologies, the market is poised for accelerated innovation and more effective treatment options, ultimately leading to faster delivery of new therapies and an expanded repertoire of solutions for patients suffering from this challenging disorder.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Gastroparesis Drugs Market Size by Type & CAGR (2026-2033)

• Market Overview
• Branded
• Generics

Global Gastroparesis Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Amino salicylates
• Digestive enzymes
• Proton Pump Inhibitors
• Laxatives
• Anti-Emetics
• H2 Antagonists
• Anti-Diarrheal
• Biologics/Biosimilar
• Others

Global Gastroparesis Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Others

Global Gastroparesis Drugs Market Size by Application & CAGR (2026-2033)

• Market Overview
• Crohn's disease
• Ulcerative colitis
• GERD
• IBS
• Others

Global Gastroparesis Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Gastroparesis Drugs Market Size & CAGR (2026-2033)

• North America (Type, Drug Class, Route of Administration, Application, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug Class, Route of Administration, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Route of Administration, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Route of Administration, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Route of Administration, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evoke Pharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vanda Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurogastrx Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Processa Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhythm Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CinDome Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ANI Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co. Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theravance Biopharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations